Koers Oncobiologics Inc Nasdaq
Aandelen
US68235M2044
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | - | Omzet 2025 * | 9,57 mln. 8,82 mln. | Marktkapitalisatie | 185 mln. 170 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -121 mln. -112 mln. | Nettowinst (verlies) 2025 * | -66 mln. -60,86 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 19,3 x |
K/w-verhouding 2024 * |
-1,41
x | K/w-verhouding 2025 * |
-3,54
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 62,99% |
Recentste transcriptie over Oncobiologics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-15 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 13-04-18 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 11-12-15 |
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+67,53% | 63,85 mld. | |
-0,77% | 41,83 mld. | |
+45,66% | 40,65 mld. | |
-10,72% | 27,12 mld. | |
+13,30% | 26,52 mld. | |
-22,79% | 18,69 mld. | |
+4,70% | 12,73 mld. | |
+24,10% | 12,11 mld. | |
+27,41% | 12,07 mld. |
- Beurs
- Aandelen
- Koers OTLK
- Koers